Sagimet Biosciences Inc., a California-based clinical-stage biopharmaceutical company specializing in the development of novel fatty acid synthase (FASN) inhibitors, announced that it will present verbalized findings from its Phase 2b FASCINATE-2 trial of denifanstat at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress 2024. The congress is set to take place from 5-8 June, 2024 in Milan, Italy.
This announcement made on May 07, 2024 signifies the company’s major progress made in its endeavors to target dysfunctional metabolic and fibrotic pathways in disease management. The presentation will revolve around the use of denifanstat, a novel FASN inhibitor, in a pathological condition known as metabolic dysfunction-associated steatohepatitis (MASH).
MASH is a liver disease that is associated with metabolic dysfunction, characterized by inflammation and accumulation of fat and fibrous tissue in the liver. Current standard therapeutic options are somewhat limited. Therefore, the development of novel therapeutics such as denifanstat represents a crucial stride in this therapeutic area.
The expected data from this FASCINATE-2 Phase 2b study could further elucidate the effectiveness and safety of denifanstat in MASH patients, which will be crucial for the clinical development program. This oral presentation at such a premiere international congress strengthens the position of Sagimet and its pioneering work in the field.
While it is still early, the data coming out from this presentation could constitute a leap forward for Sagimet Biosciences Inc. and its quest to offer innovative solutions to some of today’s most challenging health problems. The Liver Congress’ international reputation ensures that this data will reach a wide range of specialists, paving the way for future collaborations and advancements.
In conclusion, Sagimet Biosciences’ forthcoming oral presentation at the EASL International Liver Congress 2024 signifies a new chapter in the pharmaceutical sector’s efforts towards fighting complex liver diseases.
Comments